Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts
Date
2007
Authors
Abayomi, E. A.
Sissolak, G.
Jacobs, P.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Precedent from preclinical experiments coupled with two pivotal phase 2 studies in myeloma has focused attention on a potential role for ubiquitin-proteasome pathway in modulating a number of events that occur commonly in the neoplastic process involving proteins in the regulation of cells cycling, growth and differentiation. This influence is vested in the proteasomes which are large complexes of proteolytic enzymes responsible for degradation of many of these intracellular messengers. Logically interest has centred on molecules having the capacity to influence, by degradation, such molecules and although a number of agents are in development bortezomib is the only one currently in clinical use. Velcade, formerly PS-341, is a novel dipeptide boronic acid capable of reversibly inhibiting the 26S proteasome through a range of activities. The latter are anti-proliferative and proapoptotic with the latter blocking nuclear transcription via NF-κ B in addition to down regulating adhesion and inhibiting angiogenesis. Additional changes are mediated in protein folding within the endoplasmic reticulum and contribute to cell death. These concepts are given focus by considering their introduction into treatment of lymphoreticular malignancy. © 2007.
Description
Keywords
bortezomib, dexamethasone, DNA, I kappa B, immunoglobulin enhancer binding protein, proteasome inhibitor, protein p53, rituximab, vascular cell adhesion molecule 1, vasculotropin, article, B cell lymphoma, bacterial pneumonia, candidiasis, carcinogenesis, cell cycle, cell death, cell differentiation, cell growth, endoplasmic reticulum, fatigue, herpes zoster, human, hyponatremia, large cell lymphoma, lymphoma, multiple myeloma, natural killer cell, nonhodgkin lymphoma, peripheral neuropathy, positron emission tomography, T lymphocyte, thrombocytopenia, vasculitis, Active Transport, Cell Nucleus, Apoptosis, Boronic Acids, Cell Adhesion, Cell Cycle, Cell Differentiation, Clinical Trials, Phase II as Topic, Endoplasmic Reticulum, Humans, Lymphoma, Neoplasm Proteins, Neovascularization, Pathologic, NF-kappa B, Protease Inhibitors, Proteasome Endopeptidase Complex, Pyrazines, Ubiquitin
Citation
Transfusion and Apheresis Science
37
1
37
1